The development of nanomaterials to induce antigen-specific immune tolerance has shown
promise for treating autoimmune diseases. While PEGylation has been widely used to …

Targeted approaches to treat autoimmune diseases would improve upon current therapies
that broadly suppress the immune system and lead to detrimental side effects. Antigen …

Tolerogenic nanoparticles (NPs) are rapidly being developed as specific immunotherapies
to treat autoimmune disease. However, many NP-based therapies conjugate antigen (Ag) …

Immune‐mediated hypersensitivities such as autoimmunity, allergy, and allogeneic graft
rejection are treated with therapeutics that suppress the immune system, and the lack of …

Tolerogenic immunotherapy aims to blunt pathogenic inflammation without affecting
systemic immunity. However, the anti-inflammatory drugs and immunosuppressive biologics …

Antigen-specific immune tolerance has been a long-standing goal for immunotherapy for the
treatment of autoimmune diseases and allergies and for the prevention of allograft rejection …

The intravenous delivery of disease-relevant antigens (Ag) by polymeric nanoparticles (NP-
Ags) has demonstrated Ag-specific immune tolerance in autoimmune and allergic disorders …

Targeted immune tolerance is a coveted therapy for the treatment of a variety of autoimmune
diseases, as current treatment options often involve nonspecific immunosuppression …

Autoimmune diseases affect over 4% of the world's population. Treatments are generally
palliative or use broad spectrum immunosuppressants to reduce symptoms and disease …

Targeting dendritic cells with nanoparticles is an attractive modality for instigating immunity
or inducing immunosuppression. An important aspect of successful delivery of antigen and …